Kuljit Bhatia

Kuljit Bhatia, Ph.D. has extensive work experience in the pharmaceutical industry. Kuljit currently serves as the Chief Scientific Officer at Woodstock Sterile Solutions, a leading contract development and manufacturing organization (CDMO) specializing in sterile ophthalmic and respiratory dosage forms.

Prior to their current role, Dr. Bhatia worked as the Head of Global Dermatologics R&D Scientific Affairs at Viatris from 2020 to 2022. Kuljit also served as a member of the Scientific Advisory Panel at The University of Texas at San Antonio from 2012 to 2022.

Previously, Dr. Bhatia held various leadership positions at Mylan, including the Head of Global Dermatological R&D Scientific Affairs from 2016 to 2020. Kuljit also worked at DPT Laboratories as the Sr. Vice President/VP of R&D from 2012 to 2016, leading research and development activities across multiple sites.

Earlier in their career, Dr. Bhatia held positions at Nycomed/Fougera Pharmaceuticals Inc. and Medicis, where they played a key role in product development, formulation, and analytical development.

Overall, Dr. Kuljit Bhatia's work experience demonstrates their expertise in R&D strategy, product development, regulatory affairs, and CDMO management in the pharmaceutical industry.

Kuljit Bhatia, Ph.D. has a Ph.D. in Pharmaceutical Sciences from North Dakota State University. In addition, they have completed a Post Doctorate in Pharmaceutics and Drug Design at the University of Michigan.